Want to see HK:3681 full AI Analyst Report?
Top Page
SinoMab Bioscience Ltd.
(3681)
Select Model
Select Model
Rating:46Neutral
Price Target:
HK$1.00
▼(-9.09% Downside)
Action:Reiterated
Date:07/31/26
The score is primarily held down by weak financial performance (ongoing losses, cash burn, and a revenue collapse to zero), which creates funding/sustainability risk despite improved leverage and a narrower loss in 2025. Technicals are mixed—some short-term strength above the 20/50-day averages, but the stock remains below the 100/200-day averages, keeping the longer-term trend weak. Valuation is also constrained by a negative P/E and no stated dividend yield.
Positive Factors
Narrower Losses
Narrower losses in 2025 indicate some improvement in cost control or operating performance relative to the prior year. Although the company remains far from profitability, reducing the size of losses can extend financial runway and create a better base for future development and commercialization.
Negative Factors
Revenue Collapse
Revenue reaching zero shows that the business has not yet established dependable commercial scale. Persistent revenue volatility makes operating performance difficult to fund internally and leaves future growth dependent on successful product development, approvals, and eventual commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Narrower Losses
Narrower losses in 2025 indicate some improvement in cost control or operating performance relative to the prior year. Although the company remains far from profitability, reducing the size of losses can extend financial runway and create a better base for future development and commercialization.
Read all positive factors
SinoMab Bioscience Ltd. (3681) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.47B
Dividend YieldN/A
Average Volume (3M)644.65K
Price to Earnings (P/E)―
Beta (1Y)1.00
Revenue GrowthN/A
EPS Growth-4.24%
CountryHK
Employees73
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.13
Shares Outstanding1,386,638,300
10 Day Avg. Volume296,850
30 Day Avg. Volume644,650
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)2.91
Price to Sales (P/S)0.00
P/FCF Ratio-15.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.21
Revenue Forecast (FY)HK$8.71M
SinoMab Bioscience Ltd. Business Overview & Revenue Model
Company Description
SinoMab BioScience Limited is a biopharmaceutical enterprise that specializes in the comprehensive process of discovering, developing, producing, and marketing therapeutic solutions for various immunological disorders. Their approach predominantly...
How the Company Makes Money
SinoMab Bioscience primarily makes money through (1) commercialization of any approved products (e.g., sales of antibody therapeutics) and (2) out-licensing and partnering arrangements for its drug candidates, which can generate upfront payments, ...
SinoMab Bioscience Ltd. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
43
Neutral
Cash Flow
26
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 2.03M | 1.36M | 4.03M | 26.66M |
| Gross Profit | 0.00 | -26.64M | 543.00K | 422.00K | 4.03M | 26.66M |
| EBITDA | -125.75M | -72.11M | -132.89M | -200.46M | -230.89M | -285.20M |
| Net Income | -181.77M | -102.27M | -185.14M | -243.11M | -284.16M | -288.19M |
Balance Sheet | ||||||
| Total Assets | 684.46M | 908.50M | 753.10M | 847.79M | 1.01B | 1.04B |
| Cash, Cash Equivalents and Short-Term Investments | 226.21M | 382.40M | 106.88M | 234.66M | 376.19M | 589.53M |
| Total Debt | 266.78M | 338.64M | 482.27M | 450.81M | 357.18M | 275.46M |
| Total Liabilities | 323.00M | 400.41M | 560.19M | 552.20M | 498.77M | 361.43M |
| Stockholders Equity | 361.45M | 508.10M | 192.91M | 295.58M | 509.57M | 680.23M |
Cash Flow | ||||||
| Free Cash Flow | -112.79M | -95.78M | -172.30M | -237.74M | -413.29M | -345.30M |
| Operating Cash Flow | -80.23M | -70.48M | -130.80M | -133.85M | -300.54M | -147.06M |
| Investing Cash Flow | -99.30M | 16.25M | -94.48M | -96.92M | -81.36M | -137.70M |
| Financing Cash Flow | 218.96M | 329.39M | 73.27M | 82.27M | 102.28M | 57.52M |
SinoMab Bioscience Ltd. Technical Analysis
Neutral
1.10
Price Trends
1.09
Negative
1.14
Negative
1.37
Negative
Market Momentum
-0.01
Positive
48.97
Neutral
34.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3681, the sentiment is Neutral. The current price of 1.1 is above the 20-day moving average (MA) of 1.08, above the 50-day MA of 1.09, and below the 200-day MA of 1.37, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 48.97 is Neutral, neither overbought nor oversold. The STOCH value of 34.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:3681.
SinoMab Bioscience Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | HK$26.75B | 26.18 | 20.41% | ― | 32.63% | 8.74% | |
59 Neutral | HK$3.26B | 4.48 | 10.99% | ― | 1417.68% | 660.14% | |
56 Neutral | HK$17.02B | 38.23 | 15.94% | ― | 48.04% | 166.72% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$1.79B | 17.80 | 48.25% | ― | 88.38% | ― | |
47 Neutral | HK$6.06B | -30.68 | -10.27% | ― | -31.77% | -177.01% | |
46 Neutral | HK$1.47B | -6.85 | -41.81% | ― | ― | -4.24% |
* Healthcare Sector Average
HK:3681
SinoMab Bioscience Ltd.
1.07
-0.70
-39.55%
HK:6998
Genor Biopharma Holdings Limited
1.62
-1.51
-48.24%
HK:9966
Alphamab Oncology
6.22
-5.47
-46.79%
HK:2181
Mabpharm Limited
0.44
-0.09
-16.35%
HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
38.30
9.06
30.98%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
49.06
-20.04
-29.00%
SinoMab Bioscience Ltd. Corporate Events
SinoMab Clarifies Use of 2025 Share Proceeds and Share Award Details
Sep 18, 2026
SinoMab BioScience has issued a supplemental announcement to its 2025 Annual Report, clarifying how it deployed funds raised from two share subscription exercises completed in May and July 2025 under a general mandate. The company confirmed that t...
SinoMab Shareholders Unanimously Back Disposal Deal at Extraordinary Meeting
Sep 7, 2026
Shareholders of SinoMab BioScience Limited have overwhelmingly approved a key disposal transaction at an extraordinary general meeting held on 7 September 2026 in Hong Kong. The ordinary resolution to confirm, approve and ratify the sale and purch...
SinoMab Advances Antibody Pipeline With New Trials and Preclinical Milestones
Aug 31, 2026
SinoMab BioScience reported interim results for the six months to 30 June 2026, highlighting major progress across its monoclonal antibody pipeline for immune and inflammatory disorders. The board noted that all condensed interim financial stateme...
SinoMab Seeks Shareholder Approval to Sell Suzhou Industrial Property for RMB280 Million
Aug 20, 2026
SinoMab BioScience Limited has called an extraordinary general meeting in Hong Kong on 7 September 2026 for shareholders to vote on a proposed disposal of industrial property in Suzhou. The assets involved comprise state-owned construction land us...
SinoMab Schedules Board Meeting to Approve 2026 Interim Results
Aug 19, 2026
SinoMab BioScience Limited has scheduled a board meeting for 31 August 2026 to review and approve its interim results for the six months ended 30 June 2026. The meeting will also cover related matters and the subsequent publication of the half-yea...
SinoMab Sets September EGM on Major Suzhou Facility Disposal
Aug 18, 2026
SinoMab BioScience Limited, a Hong Kong–incorporated biopharmaceutical company listed on the Hong Kong Stock Exchange, develops and manufactures antibody‑based therapies and operates research and production facilities in mainland China...
SinoMab BioScience COO and Executive Director Steps Down
Aug 18, 2026
SinoMab BioScience announced that executive director and chief operating officer Fang Liang has resigned from all positions within the group, effective 18 August 2026, to pursue personal endeavours. The board stated that Liang has no disagreements...
SinoMab BioScience Clarifies Board and Committee Roles in Governance Update
Aug 18, 2026
SinoMab BioScience Limited has announced the current composition of its board of directors, led by Executive Director Dr. Shui On Leung, who serves as both chairman and chief executive officer, alongside several non-executive and independent non-e...
SinoMab Delays Dispatch of Circular on Major Suzhou Asset Disposal
Aug 10, 2026
SinoMab BioScience has announced a further delay in sending a shareholder circular related to its planned disposal of a Suzhou property and facility, a transaction classified as a major deal under Hong Kong listing rules. The circular, which will ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.